American Century Companies Inc. raised its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 1.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 343,377 shares of the biopharmaceutical company’s stock after buying an additional 3,715 shares during the quarter. American Century Companies Inc. owned approximately 0.36% of Intra-Cellular Therapies worth $18,560,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ITCI. JPMorgan Chase & Co. lifted its stake in shares of Intra-Cellular Therapies by 11.7% in the 1st quarter. JPMorgan Chase & Co. now owns 157,144 shares of the biopharmaceutical company’s stock valued at $9,615,000 after purchasing an additional 16,454 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Intra-Cellular Therapies by 5.2% during the 1st quarter. Bank of New York Mellon Corp now owns 385,508 shares of the biopharmaceutical company’s stock worth $23,591,000 after acquiring an additional 18,999 shares in the last quarter. Cambridge Investment Research Advisors Inc. acquired a new position in Intra-Cellular Therapies during the 1st quarter worth approximately $349,000. PNC Financial Services Group Inc. lifted its position in Intra-Cellular Therapies by 25.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,909 shares of the biopharmaceutical company’s stock worth $363,000 after acquiring an additional 1,204 shares in the last quarter. Finally, Natixis Advisors L.P. raised its position in shares of Intra-Cellular Therapies by 71.3% in the 1st quarter. Natixis Advisors L.P. now owns 18,165 shares of the biopharmaceutical company’s stock valued at $1,112,000 after purchasing an additional 7,558 shares in the last quarter. Hedge funds and other institutional investors own 86.94% of the company’s stock.
Intra-Cellular Therapies Trading Up 0.3 %
Shares of NASDAQ ITCI opened at $55.52 on Friday. Intra-Cellular Therapies, Inc. has a twelve month low of $42.01 and a twelve month high of $67.05. The company has a market capitalization of $5.33 billion, a price-to-earnings ratio of -28.77 and a beta of 1.09. The business has a 50 day simple moving average of $59.98 and a 200-day simple moving average of $57.98.
Analyst Ratings Changes
ITCI has been the topic of a number of recent analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $73.00 target price on shares of Intra-Cellular Therapies in a research report on Thursday, August 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $98.00 target price on shares of Intra-Cellular Therapies in a research report on Tuesday, August 22nd. Royal Bank of Canada upped their target price on Intra-Cellular Therapies from $78.00 to $79.00 and gave the company an “outperform” rating in a research report on Friday, August 4th. Mizuho upped their target price on Intra-Cellular Therapies from $74.00 to $76.00 in a research report on Monday, May 8th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $80.00 target price on shares of Intra-Cellular Therapies in a research report on Friday, August 4th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $78.78.
View Our Latest Stock Report on ITCI
Insider Buying and Selling
In related news, CFO Lawrence J. Hineline sold 81,854 shares of the company’s stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $63.97, for a total transaction of $5,236,200.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 81,854 shares of the business’s stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $63.97, for a total transaction of $5,236,200.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Suresh K. Durgam sold 1,842 shares of the business’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $65.00, for a total value of $119,730.00. Following the transaction, the executive vice president now owns 21,262 shares of the company’s stock, valued at approximately $1,382,030. The disclosure for this sale can be found here. Insiders sold a total of 138,996 shares of company stock worth $8,607,017 in the last three months. 3.40% of the stock is owned by insiders.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.
Read More
- Five stocks we like better than Intra-Cellular Therapies
- Business Services Stocks Investing
- 3 Takeaways from the August Inflation Report
- What Does a Stock Split Mean?
- On Fire: 5 Best Artificial Intelligence Penny Stocks
- Consumer Discretionary Stocks Explained
- 6 Cybersecurity Stocks: Which is the Best to Buy?
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.
